Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 23 Feb 2026. The item focuses on Corrigendum to ‘Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC’ [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828]. Review the original article for the full source wording and details.
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 23 Feb 2026.
The item focuses on Corrigendum to ‘Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC’ [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828].
Review the original article for the full source wording and details.